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See Article, pages 297–305Hepatocellular carcinoma (HCC) is a major health problem
worldwide [1], which continues to increase because of viral hep-
atitis B and C epidemics, but also because of alcoholic [2] and
non-alcoholic liver disease. HCC develops mainly in cirrhotic
livers (85–95%). In other cases, the surrounding liver is diseased
and ﬁbrous, though in some cases, the surrounding liver can be
normal.
In contrast to HCC associated with the cirrhotic liver,
non-cirrhotic HCC (NC-HCC) predominantly occurs in young
and healthy females with a peak incidence in the fourth decade.
NC-HCCs are frequently diagnosed at a late stage, with large
tumours (8–14 cm in many series). The preserved liver function
allows extensive liver resections: up to 80% of the normal func-
tional liver volume. The 5-year overall survival rates after liver
resection for NC-HCC range from 25% to 81% with a tumour-
recurrence rate of 30–73% [3]. Liver resection, thus, is currently
the best ﬁrst-line therapy for NC-HCC. However, the use of liver
transplantation (LT) in this setting has been recently discussed
in connection with unresectable HCC or because of tumour recur-
rence following initial resection.
In HCC that occurs within a cirrhotic liver, LT is theoretically
the best treatment, removing both the tumour nodules and the
underlying liver cirrhosis. However, post-LT survival can be ham-
pered by the risk of tumour recurrence, which can lead rapidly to
death [4]. For this reason, LT for HCC must be considered care-
fully, and preferably offered when there is a reasonable risk of
tumour recurrence after LT. Because LT is also an excellent treat-
ment for end-stage liver cirrhosis and because organs from
deceased donors are limited, their use should be equitable and
fair. An international consensus conference regarding LT for
HCC has been recently published [5] and emphasises that each
indication must have a comparable result, or if not, must cause
no undue prejudice to other recipients with a better prognosis.Journal of Hepatology 20
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for LT for HCC in cirrhotic patients: they give an overall 5-year
survival rate of 65–78% in different studies [6] compared to
70–82% survival for non-tumour indications according to several
registries.
We could argue that 5-year overall survival is not a good cri-
terion and that it would be better to consider the individual ben-
eﬁts to the patient, such as the survival gain offered by LT
compared to spontaneous survival predicted by prognostic mod-
els. According to this suggestion and taking into account survival
as predicted by the GRETCH score [7], LT offers a survival beneﬁt
of 52% for TNM T1 or T2 tumours, 33% for TNM T3 tumours and
25% for TNM T4A or T4B tumours (unpublished data from a
French series of 160 transplant patients). However, deceased
organs are scarce and a 5-year overall survival rate of >50% is
recommended by the liver-transplant community [8].
The paper of Mergental and co-workers [9] provides interest-
ing data on LT for NC-HCC. This work emphasises the importance
of a collaborative database to address questions regarding rare
diseases. It provides a large series of data on 105 NC-HCC trans-
plant patients, and shows 5-year overall survival of 49%. For 62
patients, liver transplantation was the primary treatment and
5-year overall survival was 43% (primary-LTs). For the other 43
patients, LT was a rescue treatment for HCC recurrence after pri-
mary liver resection (rescue-LTs), and 5-year overall survival was
58%. Pathological data showed more favourable tumour charac-
teristics in the rescue-LTs compared to primary-LTs (pTNM 7th
edition, median size of largest tumour, number of patients within
the Milan criteria and number of patients with an alpha-fetopro-
tein level <100 ng/ml). Univariate analysis of factors associated
with 5-year survival only identiﬁed pathological factors: the
number of tumours (64 vs. >4), macrovascular invasion and
lymph-node involvement. In multivariate analysis, the number
of tumours was no longer a factor, and rescue-LT for intrahepatic
recurrence within 12 months after partial liver resection was the
best predictor for 5-year survival. Five-year overall survival in
patients without macrovascular invasion and without lymph-
node involvement was 59% and reached up to 83% in the sub-
group of rescue-LT patients if LT was performed at >12 months
after primary liver resection.12 vol. 57 j 235–236
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The authors acknowledge some limitations to this study
because of its retrospective and multicentre design. However,
its major limitation is that the European Liver Transplant Registry
(ELTR) database was not originally designed to identify the
prognostics factors for liver transplantation. Indeed, the best
way to address this issue is to study HCC recurrence [10], which
is not captured by the ELTR database. Furthermore, pre-LT
tumour characteristics (imaging data at listing) should have been
recorded to test these variables in an algorithm that could indi-
cate or contra-indicate LT before pathological analysis of the
explanted liver.
It is of outmost importance to identify speciﬁc criteria associ-
ated with lymph-node involvement from pre-operative imaging.
For rescue-LT patients, the problem is even more complex
because we need to take into account the imaging characteristics
before resection, and we can take into account the pathological
characteristics of the primary resection before LT indication.
Before recommending resection, we need to access data for all
patients who have undergone resection to be able to assess the
proportion of patients that are no longer eligible for LT at the
time of recurrence.
Using the data described in this paper, and in accordance with
the international consensus statement, only patients without
pathological macrovascular invasion and without lymph-node
involvement should be referred for liver transplantation
(S5 = 59%). However, these data are analysed after transplanta-
tion on the explanted liver and the accuracy of imaging to predict
these criteria was not tested in this study. If patients were pri-
marily resected, all patients with recurrence that occurs in
>12 months after resection could be referred for LT, whatever
the pathological results of the resection and whatever the patho-
logical results of the explanted liver (S5 = 71%). Moreover,
according to the multivariate analysis, size and number of
tumours are no longer prognostic factors for overall survival after
LT for NC-HCC. However, in the largest published study of
resected NC-HCC [11], in addition to vascular invasion, tumour
size (>5 cm), number of tumours and tumour differentiation were
associated with a patient’s prognosis. Because of the complexity
of this question addressed herein, the relatively small number
of patients within this series and the previously mentioned lim-
itations, the conclusions from this study need to be handled with
caution. This study mostly underlines the need for prospective
studies in the ﬁeld of liver transplantation for HCC. We need to
systematically access the ﬁrst pre-LT images for tumour charac-
teristics, the response to treatment performed during the waiting
period, the kinetics of the tumour during the waiting period
(imaging and serological markers), and the rate of drop-out from
tumour progression. A lack of this information means no further
progress can be made to improve patient selection or to identify
new prognostic markers.236 Journal of Hepatology 201Based on this study and previously published studies, it is not
possible to recommend primary LT for NC-HCC whatever the
number and the size of HCC. Primary resection must be the stan-
dard of care for these patients and LT must be offered only for
patients with late recurrence after resection or with unresectable
HCC but with favourable prognostic factors such as AFP level
below 100 ng/ml, less than four tumours, maximum tumour
diameter of 5 cm, no vascular invasion and no lymph node
involvement assessed on imaging at listing for LT.Conﬂict of interest
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